Sterilization Validation, Site Registration and Shelf Life in Japan

1. Key takeaways

Sterilization in Japan has a dual identity: it is both an object of technical validation and an independent object of manufacturing site registration. Article 114-8 of the Implementing Rules lists sterilization among the registration-target processes, and every site that performs a sterilization process on which the sterility of the finished product depends — including contract sterilizers — must be registered. Manufacturers often assume sterilization is merely a test item; the consequence is an incomplete manufacturing site registration scope, and the application stalls at the qualification review layer before the technical content is ever examined.

• The list of registration-target processes varies by product classification and must be confirmed under Article 114-8 before site registration is planned.
• Every site performing a sterilization process on which finished-product sterility depends must be registered as a sterilization site, including third-party contract sterilizers.
• Registration of foreign manufacturers is valid for 5 years under Article 23-2-4 of the PMD Act.
• Sterilization validation documentation should be organized according to the standards established by Yakushoku Kanpatsu 1218 No. 4, December 18, 2014.
• Shelf-life argumentation must be linked with packaging verification and transport simulation in one coherent validation plan.

2. Legal basis

The dual status of sterilization rests on the process registration provisions of the Implementing Rules, the sterilization validation standards, and the foreign manufacturer registration regime. The key sources are as follows.

• Implementing Rules, Article 114-8: designation of the registration-target processes — including design, principal assembly and other principal manufacturing processes, sterilization, and domestic storage of the final product (varying according to product classification).
• Notification from the Compliance and Narcotics Division, Pharmaceutical and Food Safety Bureau, MHLW, concerning the establishment of sterilization validation standards, Yakushoku Kanpatsu 1218 No. 4, December 18, 2014.
• PMD Act Article 23-2-4, Paragraph 1: registration of foreign manufacturers; Paragraph 2: validity period of 5 years.
• PMD Act Article 23-2-5, Paragraph 2: the quality judgment criteria in approval review.
• QMS Ordinance (MHLW Ordinance No. 169 of 2004): the standards for manufacturing control and quality control, including process validation requirements.
• Current statute: Act No. 145 of 1960.

3. Expert insights

Insight 1: The list of registration-target processes changes with the classification.

Article 114-8 of the Implementing Rules specifies the registration-target processes by product classification: for general medical devices, design-related processes are not included; for programmable medical devices, design alone is the registration target; while Class II through Class IV devices cover design, principal assembly, sterilization, and domestic storage of the final product. When planning the scope of manufacturing site registration, companies must first determine the product classification. Getting the classification wrong in either direction creates problems: registering processes that are not required wastes effort and exposes sites to unnecessary oversight, while omitting a required process leaves a statutory gap that formal review will catch. The classification decision therefore precedes and governs the entire registration plan. Where the product falls under the approval route rather than certification, the same discipline applies through the quality judgment criteria of the approval review, which likewise depend on the registration scope being established correctly from the start.

Insight 2: Contract sterilizers must also register — a hard constraint on supply chain management.

Every site that performs a sterilization process on which the sterility of the finished product depends must be registered as a sterilization site, including third parties performing contract sterilization. This means the selection of a sterilization supplier must take into account its willingness and ability to cooperate with registration — it cannot be made on cost alone. A supplier that cannot or will not support Japanese site registration effectively disqualifies itself, regardless of price or technical capability. Building this requirement into supplier qualification criteria before contracts are signed avoids the situation in which a validated process must be moved to a different provider because the original one cannot be registered.

Insight 3: Shelf-life argumentation must cover the packaging and transport stages.

Stability and shelf-life documentation must be argued in connection with the packaging format and the transport conditions. GRZAN typically requires, in its Japan projects, that packaging verification, transport simulation, and shelf-life testing be combined into one coherent validation plan, so that the conclusions of the three parts do not contradict one another; planning for packaging and transport from the start also avoids a second round of testing when the distribution conditions are questioned later. A shelf-life claim supported by stability data alone leaves open how the sterile barrier and the product survive real distribution, and reviewers may ask exactly that question. A single, connected validation report — packaging, transport, and shelf life — closes the chain from manufacturing to the end user and removes the gaps that separate submissions tend to leave.

4. Practical recommendations

• Determine the registration-target process list according to the classification. Follow Article 114-8 of the Implementing Rules and confirm the registration scope for each manufacturing site.
• Front-load the compliance assessment in sterilization supplier selection. Write the ability to cooperate with Japanese manufacturing site registration into the supplier admission criteria.
• Organize the sterilization validation documentation according to Yakushoku Kanpatsu 1218 No. 4. Self-check the completeness of the three parts — validation plan, implementation records, and conclusions — before submission.
• Validate shelf life jointly with packaging and transport. Produce one coherent validation report, avoiding separate submissions whose conclusions conflict.

5. Verification checklist

• □ Has the registration-target process list for this product been confirmed under Article 114-8 of the Implementing Rules?
• □ Have all sites performing sterilization processes on which finished-product sterility depends (including contract sterilizers) been registered?
• □ Is the registration of the foreign manufacturer within its 5-year validity period?
• □ Has the sterilization validation documentation been organized according to Yakushoku Kanpatsu 1218 No. 4 (December 18, 2014)?
• □ Has the shelf life been argued jointly with packaging verification and transport simulation?

Legal information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, in-country representative and local testing support for the Japanese market. Our team prepares J-GCP/J-QMS compliant dossiers, coordinates conformity assessments, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com